Skip to content
Menu

Neurocrine Biosciences, Inc. NBIX

Full chart Compare
Set alert

Price alert · NBIX

All alert types
150.57 USD -6.02 (-3.84%)

Regular-session close

150.57 0.00 0.00%

After hours · Nov 20, 5:23 PM ET

150.24 Day range 158.26
123.10 52-week range 185.50
YTD
+6.16%
1 year
+8.34%

5D -17.48 (-10.40%)

150160MonTueWedThuFri150.57
Market cap
15.24B
Revenue (ttm)
3.70B
Profit margin
18.98%
EPS (ttm)
6.74
Shares out
101.22M
P/E ratio
22.34
Forward P/E
12.24
YTD return
+6.16%
1-year return
+8.34%
50-day average
149.14
Volume
1.59M
Avg volume
1.33M
Open
156.27
Previous close
156.59
Day's range
150.24 – 158.26
52-week range
123.10 – 185.50
Beta
0.33
Analysts
Strong Buy
Price target
208.54 (+38.5%)
Earnings date
Feb 10, 2027

Key statistics

200-day average
149.38
Enterprise value
15.56B
PEG ratio
0.32
Price / sales
4.12
Price / book
3.93
Revenue growth
41.20%
Free cash flow
1.02B
Total cash
737.90M
Total debt
451.80M
Return on equity
20.41%
Short % of float
7.58%

Fundamental scorecard

18 of 25 checks passed on NBIX’s reported financials

ValueGrowthProfitabilityHealthDividend

18of 25 checks passed

  • Value 4 of 5
  • Growth 4 of 5
  • Profitability 5 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NBIX Revenue — quarterly 1.12B
NBIX Net income — quarterly 206.50M
NBIX EPS — quarterly 2.03

Earnings

NBIX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 10, 2027Dec 30, 20262.07———
Nov 2, 2026Sep 30, 20261.913.29+1.38+72.25%
Jul 30, 2026Jun 30, 20261.852.85+1.00+54.05%
May 5, 2026Mar 31, 20261.221.91+0.69+56.56%
Feb 11, 2026Dec 31, 20251.801.88+0.08+4.44%
Oct 28, 2025Sep 30, 20251.582.04+0.46+29.11%

Upgrades / downgrades

NBIX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 13, 2026Morgan StanleymainEqual-WeightEqual-Weight
Nov 4, 2026GuggenheimmainBuyBuy
Nov 3, 2026Morgan StanleymainEqual-WeightEqual-Weight
Nov 3, 2026RBC CapitalmainOutperformOutperform
Nov 3, 2026Canaccord GenuitymainBuyBuy
Nov 3, 2026Piper SandlermainOverweightOverweight

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on NBIX — it syncs with the Stock Master app.

Insider holders

NBIX insider holders
InsiderRelationLatest transactionDateShares held
ABERNETHY MATTHEW CChief Financial OfficerSaleSep 13, 202642,808
BENEVICH ERIC S.OfficerStock Award(Grant)Sep 10, 202667,297
COOKE JULIE SMITHOfficerStock Award(Grant)Sep 10, 202624,025
GANO KYLE WChief Executive OfficerConversion of Exercise of derivative securityOct 29, 2026155,010
GORMAN KEVIN CHARLESDirectorStock Award(Grant)Sep 10, 2026517,797
LIPPOLDT DARIN MOfficerStock Award(Grant)Sep 10, 202656,793

Institution ownership

NBIX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.14.68%14,856,1032.24BSep 29, 2026
Dodge & Cox Inc.5.44%5,504,578828.82MSep 29, 2026
JPMORGAN CHASE & CO5.23%5,292,589796.91MSep 29, 2026
Vanguard Portfolio Management LLC5.00%5,060,036761.89MSep 29, 2026
State Street Corporation4.75%4,807,975723.94MSep 29, 2026
Vanguard Capital Management LLC4.53%4,580,803689.73MSep 29, 2026

Fund ownership

NBIX fund ownership
Holder% heldSharesValueReported
Dodge & Cox Funds-Dodge & Cox Stock Fund3.92%3,964,000596.86MJun 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF3.58%3,620,760545.18MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.15%3,193,267480.81MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.28%2,304,996347.06MJun 29, 2026
J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd.1.34%1,358,475204.55MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.31%1,329,829200.23MJun 29, 2026